Australia markets open in 9 hours 4 minutes
  • ALL ORDS

    7,442.00
    +23.40 (+0.32%)
     
  • AUD/USD

    0.6716
    +0.0059 (+0.88%)
     
  • ASX 200

    7,253.30
    +24.20 (+0.33%)
     
  • OIL

    78.62
    +1.38 (+1.79%)
     
  • GOLD

    1,766.50
    +11.20 (+0.64%)
     
  • BTC-AUD

    24,450.17
    +176.22 (+0.73%)
     
  • CMC Crypto 200

    387.79
    +7.50 (+1.97%)
     

uniQure to Participate in Upcoming Industry Conferences in October

uniQure Inc.
uniQure Inc.

LEXINGTON, Mass. and AMSTERDAM, Oct. 03, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:

  • Chardan’s 6th Annual Genetic Medicines Conference, October 3 – 4, 2022

    • Members of uniQure’s management team, including Ricardo Dolmetsch, Ph.D., president of research and development, will participate in one-on-one investor meetings on Monday, October 3.

    • A fireside chat with Dr. Dolmetsch will take place the same day from 8:30 to 8:55 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Media section of the uniQure website.

  • European Society of Gene & Cell Therapy (ESGCT), October 11 – 14, 2022

    • uniQure will present multiple preclinical data on its programs in temporal lobe epilepsy, Alzheimer’s disease and amyotrophic lateral sclerosis (ALS), along with key features of its AAV manufacturing process development. Specific details will follow when meeting abstracts are released.

  • 2022 Latin American Huntington’s Disease Conference, October 19 – 21, 2022

    • Dr. Dolmetsch will present an overview of uniQure’s clinical development program of AMT-130 in Huntington’s disease on Thursday, October 20.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other diseases. www.uniQure.com

uniQure Contacts:

 

 

 

 

 

FOR INVESTORS:

 

FOR MEDIA:

 

 

 

Maria E. Cantor

Chiara Russo

Tom Malone

Direct: 339-970-7536

Direct: 617-306-9137

Direct: 339-970-7558

Mobile: 617-680-9452

Mobile: 617-306-9137

Mobile:339-223-8541

m.cantor@uniQure.com

c.russo@uniQure.com

t.malone@uniQure.com